These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23629717)

  • 1. Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.
    Amsden JR; Gubbins PO; McConnell S; Anaissie E
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3420-3. PubMed ID: 23629717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole: review of a broad spectrum triazole antifungal agent.
    Kofla G; Ruhnke M
    Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update on voriconazole].
    Dtsch Med Wochenschr; 2003 Aug; 128(33):1738. PubMed ID: 12968630
    [No Abstract]   [Full Text] [Related]  

  • 4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis caused by Aspergillus fumigatus.
    Xiang-Gen W; Li-Na Y; Meng X; Hao-Ran J
    J Pharm Sci; 2011 May; 100(5):1745-59. PubMed ID: 21374612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Brown J; Freeman BB
    Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole pharmacokinetics in liver transplant recipients.
    Johnson HJ; Han K; Capitano B; Blisard D; Husain S; Linden PK; Marcos A; Kwak EJ; Potoski B; Paterson DL; Romkes M; Venkataramanan R
    Antimicrob Agents Chemother; 2010 Feb; 54(2):852-9. PubMed ID: 19933807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
    Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
    J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravitreally implantable voriconazole delivery system for experimental fungal endophthalmitis.
    Yang L; Dong X; Wu X; Xie L; Min X
    Retina; 2011 Oct; 31(9):1791-800. PubMed ID: 21606889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients.
    Mori M; Fukushima K; Miharu M; Goto H; Yoshida M; Shoji S
    J Infect Chemother; 2013 Feb; 19(1):174-9. PubMed ID: 22714745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the dose of voriconazole compensates for enzyme induction by phenytoin.
    Spriet I; Meersseman P; Meersseman W; de Hoon J; Willems L
    Br J Clin Pharmacol; 2010 Jun; 69(6):701-2. PubMed ID: 20565462
    [No Abstract]   [Full Text] [Related]  

  • 14. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.
    Stern JB; Girard P; Caliandro R
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1065. PubMed ID: 14982812
    [No Abstract]   [Full Text] [Related]  

  • 15. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
    Aperis G; Mylonakis E
    Expert Opin Investig Drugs; 2006 Jun; 15(6):579-602. PubMed ID: 16732713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole in clinical practice.
    Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
    J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
    Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
    J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.
    Mohammedi I; Piens MA; Padoin C; Robert D
    Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
    Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
    J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.
    Tell LA; Clemons KV; Kline Y; Woods L; Kass PH; Martinez M; Stevens DA
    Med Mycol; 2010 Mar; 48(2):234-44. PubMed ID: 19548171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.